Background: Hemophilias are relatively common coagulopathies that requíre very careful management to prevent bleeding and related complications. Objective: To review the current management of hemophilias, with an overview of gene therapy. Although with the availability of highly purified and recombinant factor concentrates the replacement therapy of hemophilias has become safer and more effective, a therapeutic method providing continuous supply of clotting factors is desirable. Theoretically, this is possible, by transplanting organs, than can express antihemophilic proteins, but in most cases a less invasive method is preferable. Therefore the gene therapy would be revolutionary in treating hemophiliacs. Conclusion: The treatment of choice for hemophilias is the infusion of highly purified or recombinant factor products. Although still in experimental level, gene therapy for hemophilias is promising and may become the treatment of choice in these disorders.
|Number of pages||8|
|Journal||Acta physiologica Hungarica|
|Publication status||Published - Dec 1 1996|
- Gen therapy
ASJC Scopus subject areas
- Physiology (medical)